---
title: "IDEAYA shares ESMO 2026 data updates for darovasertib trials in uveal melanoma"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293040241.md"
description: "IDEAYA Biosciences announced new clinical data for darovasertib in uveal melanoma at ESMO 2026. Partner Hengrui plans to present long-term Phase 1 results for IDE849 (SHR-4849) in relapsed small cell lung cancer and other NECs, targeting the start of its first registrational trial by year-end in China and other regions including the US."
datetime: "2026-07-17T13:00:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293040241.md)
  - [en](https://longbridge.com/en/news/293040241.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293040241.md)
generator: "portal-rs"
---

# IDEAYA shares ESMO 2026 data updates for darovasertib trials in uveal melanoma

-   IDEAYA Biosciences flagged new clinical data disclosures at ESMO 2026 for darovasertib across metastatic and neoadjuvant uveal melanoma programs. \* Partner Hengrui plans to present long-term Phase 1 results for IDE849 (SHR-4849), a DLL3 TOP1 ADC, in relapsed small cell lung cancer and other NECs. \* Hengrui targets starting the first registrational trial for IDE849 by year-end in China, with initiation also planned in other regions including the US. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607170900PR\_NEWS\_USPR\_\_\_\_\_SF06795) on July 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [IDYA.US](https://longbridge.com/en/quote/IDYA.US.md)
- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)

## Related News & Research

- [HENGRUI PHARMA  1H26 Net Profit Rises 0.3% YoY to RMB4.465 Billion; Shares Now Down Over 7%](https://longbridge.com/en/news/296422700.md)
- [Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78](https://longbridge.com/en/news/296368941.md)
- [Lytix Biopharma partners on Phase II ALETTA trial of ruxotemitide with ipilimumab, nivolumab in resectable melanoma](https://longbridge.com/en/news/297066836.md)
- [BriaCell says Bria-MEL+ melanoma vaccine candidate hits genetic engineering milestone](https://longbridge.com/en/news/296780600.md)
- [Biovica says DiviTum TKa study in metastatic melanoma is published in Clinical Cancer Research](https://longbridge.com/en/news/296871354.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**